Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immunovant, Inc. Director's Dealing 2023

Apr 14, 2023

31436_dirs_2023-04-14_9b62bbf8-4809-42ae-90ef-a216553b8f75.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2023-04-12

Reporting Person: Torti Frank (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-04-12 Common Stock A 121916 Acquired 515274 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-04-12 Stock Option (right to buy) $14.7 A 158292 Acquired 2033-04-12 Common Stock (158292.0) Direct

Footnotes

F1: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2: The RSUs vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

F3: Shares underlying the options vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date.